Revolution Medicines reported updated Phase 1/2 RMC-GI-102 data showing a 60.7% confirmed objective response rate for RASONQUE plus chemotherapy in first-line metastatic pancreatic cancer, alongside ...
Source LinkRevolution Medicines reported updated Phase 1/2 RMC-GI-102 data showing a 60.7% confirmed objective response rate for RASONQUE plus chemotherapy in first-line metastatic pancreatic cancer, alongside ...
Source Link
Comments